An HPF1/PARP1-Based Chemical Biology Strategy for Exploring ADP-Ribosylation.


Journal

Cell
ISSN: 1097-4172
Titre abrégé: Cell
Pays: United States
ID NLM: 0413066

Informations de publication

Date de publication:
12 11 2020
Historique:
received: 27 04 2020
revised: 27 07 2020
accepted: 22 09 2020
entrez: 13 11 2020
pubmed: 14 11 2020
medline: 20 5 2021
Statut: ppublish

Résumé

Strategies for installing authentic ADP-ribosylation (ADPr) at desired positions are fundamental for creating the tools needed to explore this elusive post-translational modification (PTM) in essential cellular processes. Here, we describe a phospho-guided chemoenzymatic approach based on the Ser-ADPr writer complex for rapid, scalable preparation of a panel of pure, precisely modified peptides. Integrating this methodology with phage display technology, we have developed site-specific as well as broad-specificity antibodies to mono-ADPr. These recombinant antibodies have been selected and characterized using multiple ADP-ribosylated peptides and tested by immunoblotting and immunofluorescence for their ability to detect physiological ADPr events. Mono-ADPr proteomics and poly-to-mono comparisons at the modification site level have revealed the prevalence of mono-ADPr upon DNA damage and illustrated its dependence on PARG and ARH3. These and future tools created on our versatile chemical biology-recombinant antibody platform have broad potential to elucidate ADPr signaling pathways in health and disease.

Identifiants

pubmed: 33186521
pii: S0092-8674(20)31252-6
doi: 10.1016/j.cell.2020.09.055
pii:
doi:

Substances chimiques

Antibodies 0
Benzimidazoles 0
Carrier Proteins 0
HPF1 protein, human 0
Histones 0
Nuclear Proteins 0
Phosphates 0
Phthalazines 0
Piperazines 0
Recombinant Proteins 0
veliparib 01O4K0631N
Tyrosine 42HK56048U
Serine 452VLY9402
PARP1 protein, human EC 2.4.2.30
Poly (ADP-Ribose) Polymerase-1 EC 2.4.2.30
Phosphoric Monoester Hydrolases EC 3.1.3.2
Glycoside Hydrolases EC 3.2.1.-
ADPRS protein, human EC 3.2.1.143
olaparib WOH1JD9AR8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1086-1102.e23

Informations de copyright

Copyright © 2020 Elsevier Inc. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Interests I.M., J.J.B., and T.C. are inventors on EU patent applications PCT/EP2018/078592 and PCT/EP2019/074885 filled by the Max Planck Society and related to the technology for site-specific generation of Ser-ADP-ribosylated peptides.

Auteurs

Juan José Bonfiglio (JJ)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.

Orsolya Leidecker (O)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.

Helen Dauben (H)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.

Edoardo José Longarini (EJ)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.

Thomas Colby (T)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.

Pablo San Segundo-Acosta (P)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany.

Kathryn A Perez (KA)

Protein Expression and Purification Core Facility, EMBL Heidelberg, 69126 Heidelberg, Germany.

Ivan Matic (I)

Research Group of Proteomics and ADP-ribosylation Signaling, Max Planck Institute for Biology of Ageing, 50931 Cologne, Germany; Cologne Excellence Cluster for Stress Responses in Ageing-Associated Diseases (CECAD), University of Cologne, 50931 Cologne, Germany. Electronic address: imatic@age.mpg.de.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH